Sanofi secured a significant win as the European Union granted approval for its latest multiple sclerosis treatment. The regulatory green light arrives as a strategic recovery for the French pharmaceutical giant, following a rejection from U.S. authorities earlier this year.

Simultaneously, federal health officials introduced a series of regulatory reforms aimed at accelerating domestic drug development. By streamlining the safety study process, officials hope to shave six to twelve months off the timeline for new treatments to reach patients. The initiative specifically targets the growing trend of pharmaceutical companies off-shoring research and development, seeking to restore the U.S. as a primary hub for medical innovation.